´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº°-»ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Diabetic Retinopathy Therapeutic Market, By Diabetic Retinopathy Type, By Treatment Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1606457
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,518,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,464,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,855,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â 91¾ï 932¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.88%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-½ÃÀå ¿ªÇÐ

´ç´¢º´ ¹× ´ç´¢º´¼º ¸Á¸·ÁõÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ö¿ä ÃËÁø

¼¼°è ´ç´¢º´ ÀÌȯÀ² »ó½ÂÀ¸·Î ´ç´¢º´¼º ¸Á¸·ÁõÀÌ ¹ßº´ÇÏ´Â »ç¶÷ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æ°ü¸®¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹ÀÇ ¸ðµç ¿¬·ÉÃþ¿¡¼­ ÃßÁ¤ 960¸¸ ¸íÀÌ ´ç´¢º´¼º ¸Á¸·º´ÁõÀÌ ¹ßº´Çß½À´Ï´Ù. ±×·¯³ª Ä¡·á ·¹Áö¸àÀÇ º¹À⼺À̳ª Ä¡·áÀÇ ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀº ȯÀÚ°¡ 󹿹ÞÀº Ä¡·á °èȹÀ» Áöų ÀÇ¿åÀ» ÀÒ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×¿Í ¹Ý´ë·Î ´ç´¢º´¼º ¸Á¸·Áõ °ü¸®¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Á¶»ç¿Í ±â¼úÀÇ Áøº¸´Â ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ´õ¿íÀÌ ´ç´¢º´ ȯÀÚÀÇ Á¤±âÀûÀÎ ¾È°ú °ËÁøÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÇ °íÁ¶´Â ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ °¡Á®¿É´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 6.88%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°·Î, ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·ÁõÀº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³½ °ÍÀ¸·Î Æò°¡µË´Ï´Ù.

Ä¡·á À¯Çüº°·Î, 2023³â¿¡ Ç×Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VGEF) ¾à¹°ÀÌ ÁÖ¿ä ºÎ¹®À̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹ÌÀÇ ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀÌ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀº ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° ¹× Áö¿ªº°·Î ¼¼ºÐÈ­µË´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°·Î´Â Áõ½Ä ´ç´¢º´¼º ¸Á¸·Áõ°ú ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·ÁõÀÇ µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·Áõ ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ´ç´¢º´ ȯÀÚÀÇ ³ôÀº À¯º´·ü, Á¶±â ¹ß°ß ¹× Ä¡·á ¿É¼ÇÀÇ ÀÎÁöµµ¿Í ÀÔ¼ö °¡´É¼º Çâ»ó¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î ¾È°ú¼¾ÅÍ, º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ, ±âŸ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ¾î ¿¹Ãø ±â°£ Áß¿¡µµ ±× ¿ìÀ§¼ºÀº À¯ÁöµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ¿ìÀ§¼ºÀº ÁÖ·Î ´ç´¢º´¼º ¸Á¸·ÁõÀ» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ÇʼöÀûÀÎ °íµµÀÇ Áø´Ü µµ±¸¿Í ¿Ü°úÀû °³ÀÔÀ» Æ÷ÇÔÇÑ Æ÷°ýÀûÀÎ Äɾ Á¦°øÇÏ´Â º´¿øÀÇ ´É·Â¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-Áö¸®Àû ÀλçÀÌÆ®

Áö¸®ÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀº ºñÁî´Ï½º¸¦ ¼±µµÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ³ª´¹´Ï´Ù.

´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-°æÀï ±¸µµ :

´ç´¢º´¼º ¸Á¸·ÁõÀÇ À¯º´·ü Áõ°¡´Â Çõ½ÅÀûÀÎ Ä¡·á Àü·«°ú Á¾ÇÕÀûÀΠȯÀÚ Äɾ ´ëÇÑ ÁÖ·ÂÀ» Ư¡À¸·Î ÇÏ´Â °æÀï ±¸µµ¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿ø°ÝÀǷᳪ µðÁöÅÐ Çコ ¼Ö·ç¼Ç µîÀÇ ¼±Áø ±â¼úÀ» Ȱ¿ëÇØ, ȯÀÚÀÇ ÀΰÔÀÌÁö¸ÕÆ®¸¦ ³ô¿©, Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ´ç´¢º´¼º ¸Á¸·ÁõÀÇ ´Ù¾çÇÑ º´±â¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â ½Å±Ô Ä¡·á¹ýÀ» µµÀÔÇϱâ À§ÇØ, ¸¹Àº Á¶Á÷ÀÌ ¿¬±¸ °³¹ßÀ» ¿ì¼±ÇØ, ¾È¸ÞÆ® ¸ÞµðÄà ¿ä±¸¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾî Á¦°ø¾÷ü³ª ¿¬±¸±â°ü°úÀÇ Á¦ÈÞ³ª ÆÄÆ®³Ê½Êµµ ÀϹÝÀûÀÎ Àü·«À̸ç, À̸¦ ÅëÇØ ±â¾÷Àº ½ÃÀåÀ¸·ÎÀÇ ¸®Ä¡¸¦ È®´ëÇϰí Ä¡·á ¼º°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á »ê¾÷ ¿¬±¸

Á¦5Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå »óȲ

Á¦7Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°

Á¦8Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°

Á¦9Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : Áö¿ª

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.

Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.

Diabetic Retinopathy Therapeutic Market- Market Dynamics

Increasing prevalence of diabetes and diabetic retinopathy to propel market demand

The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.

Diabetic Retinopathy Therapeutic Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)

Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023

Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023

On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023

Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:

The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.

The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.

The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.

Diabetic Retinopathy Therapeutic Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Retinopathy Therapeutic Market- Competitive Landscape:

The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.

Recent Developments:

In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Diabetic Retinopathy Therapeutic Market Overview

2. Executive Summary

3. Diabetic Retinopathy Therapeutic Key Market Trends

4. Diabetic Retinopathy Therapeutic Industry Study

5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions

6. Diabetic Retinopathy Therapeutic Market Landscape

7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type

8. Diabetic Retinopathy Therapeutic Market - By Treatment Type

9. Diabetic Retinopathy Therapeutic Market - By End User

10. Diabetic Retinopathy Therapeutic Market- By Geography

11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â